Epocrates (EPOC) IPOreport
  Back | Forward               Analysts  Corner  Archives
AcelRx Pharmaceuticals (ACRX)

Epocrates (EPOC) $75 million IPO with a market capitalization of $312 million at the price range mid-point of $14 is scheduled for Wednesday, February 2, 2011

CONCLUSION

EPOC looks expensive based on low top line revenue growth and very high Price/Earnings ratio

Slow top line revenue growth

. Revenue up 10% comparing September nine months for 2010 and 2009
. Revenue up 13% comparing 2009 with 2008

P/E is 213, annualizing results for the nine months ended September 2010

Valuation Ratios

IPO Mrkt

Price /

Price /

Price /

Price /

annualizing Sept 9 mos

Cap (mm)

Sales

Earnings

BookValue

TangibleBV

Epocrates (EPOC)

$312

3.2

213

5.9

8.5

BUSINESS

. Provides mobile drug reference tools to healthcare professionals and interactive services to the healthcare industry.

. EPOC believes its products help healthcare professionals make more informed prescribing decisions, enhance patient safety and improve practice productivity.

USER NETWORK & PLATFORMS

. User network consists of over one million healthcare professionals, including over 300,000, or over 45% of, U.S. physicians.
. U.S. mobile platforms include Apple® (iPhone®, iPod touch® and iPad™), Android™, BlackBerry®, Palm® and Windows® Mobile devices.
. To date, jas worked with all of the top 20 global pharmaceutical companies by sales and over 350 individual pharmaceutical brands to engage with healthcare professionals through EPOC’s interactive services.

STRONG BRAND

Drug references

. EPOC believes physicians trust Epocrates for accurate content and innovative offerings and use EPOC products more than any other mobile drug reference tool.

. Healthcare professionals access information such as dosing, drug/drug interactions, pricing and insurance coverage for thousands of brand, generic and over-the-counter drugs.

Market research

. Provides the healthcare industry, primarily pharmaceutical companies, access to our user network to deliver targeted information and conduct market research in a cost-effective manner.
. Services include DocAlert® clinical messages that deliver product news and alerts to healthcare professionals.

Virtual Representative Services
Including drug detailing, sampling, patient literature delivery and the ability to contact drug manufacturers, are designed to supplement and replicate the activities of pharmaceutical sales representatives.

COMPETITION

Competes with other companies in two primary areas

. For users of the types of clinical information EPOC offers
. For budget dollars from pharmaceutical clients.

Drug and clinical reference tools
Competes with Medscape, a division of WebMD, LLC, and UpToDate Inc., among others.

Interactive services

Competes with Medscape, Physicians Interactive and others that provide:healthcare-related online portals and other websites that attract physicians by providing clinical information; and electronic detailing, electronic newsletters and other electronic marketing companies.

Market research business

. Competes with firms such as Medefield America and All Global, among others. Both of these firms recruit physicians to participate in surveys, often by phone, fax, email or traditional mail.
. Also competes with the recruitment divisions of market research companies that have assembled their own survey panels of healthcare professionals.

Electronic health records

EPOC plans to enter the EHR market and expects to compete with companies selling EHR solutions to solo and small group physician practices, which include eClinicalWorks, Allscripts and others.

USE OF PROCEEDS

$44mm from sales of 3.6mm shares. Shareholders intend to sell 1.8mm shares

. $29mm (66%) to pay deferred dividends

. Balance for general corporate purposes

Epocrates (EPOC)

EPOC, C+, 7

Post IPO shares: 22.3mm

Moble drug ref tools

San Mateo CA

2007

2008

2009

Sept9mos09

Sept9mos10

IPO Mkt

Revenues ($mm)

$66

$83

$94

$66

$73

Cap (mm)

Gross margin % of rev

35%

30%

31%

33%

32%

$312

Net income (loss)

$26

$7

$8

$4

$1

@$14

Net income % of rev

39%

9%

8%

6%

2%

Valuation Ratios

IPO Mrkt

Price /

Price /

Price /

Price /

% offered

annualizing Sept 9 mos

Cap (mm)

Sales

Earnings

BookValue

TangibleBV

in IPO

Epocrates (EPOC)

$312

3.2

213

5.9

8.5

24%

SCORECARD

Mgt

Market

Market Do-

Proprie-

Total

1-5, 5 is high

Growth

mination

tary

rating

20 is perfect

2

2

2

1

7